Results 101 to 110 of about 2,751,693 (208)

The Relationship Between Bcr-Abl1 Related MicroRNA's Expression Levels And Imatinib Resistance In Chronic Myeloid Leukemia Cases

open access: yesVan Tıp Dergisi
INTRODUCTION: BCR-ABL fusion gene is targeted in the treatment of chronic myeloid leukemia and is essential in its follow-up. MicroRNAs are small RNA molecules with oncogenic and tumor suppressor properties.
Omer Yakar   +3 more
doaj   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

open access: yesTumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James   +9 more
doaj   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo   +8 more
wiley   +1 more source

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease [PDF]

open access: yes, 2003
FIP1L1-PDGFRα causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib (Gleevec). Imatinib is a potent inhibitor of ABL, ARG, PDGFRα, PDGFRβ, and KIT and induces durable hematologic responses in HES patients ...
Neuberg, Donna   +22 more
core   +1 more source

Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance

open access: yesMolecular Cancer, 2018
Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in imatinib-resistant gastrointestinal stromal tumor (GIST). 20 genes and 2 miRNAs have been selected by total reads of sgRNA and sgRNA diversity, which has been further
Jie Cao   +13 more
doaj   +1 more source

Small‐Molecule Kinase Inhibitors Modulating Circadian Rhythms

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1735-1752, November 2026.
ABSTRACT The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...
Irene Castellino   +3 more
wiley   +1 more source

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

open access: yes, 2005
The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance to imatinib are leading to relapses in some patients. In addition to inhibiting
Doggrell, Sheila A.   +2 more
core   +1 more source

Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation

open access: yesRespirology, Volume 31, Issue 11, Page 1077-1090, November 2026.
ABSTRACT Asthma is a heterogeneous syndrome featuring variable pathophysiology, clinical presentation and treatment response. This review examines a comprehensive endotype‐phenotype framework for asthma assessment with an emphasis on characteristics beyond T2 inflammatory status alone.
Mario Fernando, Gregory G. King
wiley   +1 more source

Imatinib resistance in chronic myelogenous leukemia: an emerging challenge [PDF]

open access: yes, 2017
Resistance to imatinib is a significant clinical issue, and the underlying mechanism of this resistance is multifactorial. The efficacy of imatinib in chronic myeloid leukemia (CML) in achieving a high remission rate and improving prognosis has seriously
Yeshwante, Prashant S.   +3 more
core  

Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia

open access: yesGlobal Medical Genetics
Background/Objectives: Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease driven by the BCR-ABL1 fusion oncogene. Tyrosine kinase inhibitors (TKIs) such as Imatinib mesylate have dramatically improved patient outcomes, yet ...
Petar Petrov Donchev   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy